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Statin therapy is associated with aneurysm sac
regression after endovascular aortic repair
Maxime Raux, MD, Frédéric Cochennec, MD, and Jean-Pierre Becquemin, MD, Créteil, France
Background: Several anatomic factors have been identified as predictive of sac behavior after endovascular aneurysm repair
(EVAR). The effects of statin therapy on aneurysm sac size reduction remain controversial. This study tested the
hypothesis that statin therapy enhances aneurysmal sac regression after EVAR.
Methods:This monocentric retrospective study included patients with abdominal aortic aneurysms treated by EVAR using
the Zenith (Cook, Bloomington, Ind) graft device. We excluded patients presenting with perioperative sac enlargement
factors such as endoleaks, endotension, infectious, inflammatory, ruptured, or anastomotic aneurysms. We prospectively
assessed standard clinical and anatomic data, as well as statin use, at the time of EVAR and during follow-up. The primary
end point was the decrease in the largest transverse aortic diameter at 24 months compared with the preoperative
diameter.
Results: Among 166 patients treated by a Zenith device and meeting the inclusion criteria, 120 were identified as statin
users and 46 as nonstatin users, with comparable characteristics. At 24 months of follow-up, statin group patients had a
greater aneurysm sac reduction (25% vs 14%; P < .0001). At a threshold of 5 mm in diameter regression, statin use was
a positive factor of retraction (odds ratio, 7.93; 95% confidence interval, 3.22-15.52; P < .0001). Multivariate analysis
revealed statin use was an independent predictive factor of sac regression (adjusted odds ratio, 9.39; 95% confidence
interval, 3.45-25.56).
Conclusions: This study showed that statin use was predictive of sac regression after EVAR with the Zenith graft device.
This effect needs to be confirmed by larger randomized trials or by large population evaluation. (J Vasc Surg 2012;55:
1587-92.)
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BTo date, the benefits of statin therapy on morbidity
and mortality of patients with high cardiovascular risk
factors are no longer questioned. Statins (3-hydroxyl-3-
methylglutaryl coenzyme A reductase inhibitors) reduce
triglyceride, total cholesterol, and low-density lipoprotein
levels and increase the high-density lipoprotein level.1
Large trials and studies have shown a beneficial role of
long-term statin therapy on cardiovascular mortality and
morbidity rates,2,3 stroke prevention,4 and on peripheral
arterial diseases.5 Furthermore, statins have demonstrated
many biologic effects, also known as pleiotropic effects,
including anti-inflammatory activity,6 decreasing proteases
activity involved in aneurysm disease,7,8 and improvement
of endothelial function.9,10
There is evidence that abdominal aortic aneurysm
(AAA) formation is associated with inflammation, endothe-
lial dysfunction, and proteolysis as a consequence of a gap
between proteases and their inhibitors in the arterial wall,
resulting in destruction of the elastic media.11,12 The ability
of statins to reduce these biologic adverse effects might
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doi:10.1016/j.jvs.2011.12.040xplain why many studies have suggested beneficial effects
n postoperative outcomes13 or on AAA evolution.14-17
he latter still remains controversial. In a recent meta-
nalysis, Twine et al18 found no influence of statin therapy
n AAA expansion rate.
Endovascular aneurysm repair (EVAR) has become a
ainstay of AAA treatment. Three randomized trials19-21
nd studies of international registries22 have demonstrated
he short-term benefits of EVAR over open surgical repair.
he aim of EVAR is to prevent rupture by reducing the
ressure on the arterial wall. One of the consequences of
his effect is a retraction of the sac. Anatomic predictive
actors of sac retraction have been identified,23 but no study
o far has demonstrated beneficial effects of drugs on sac
egression after EVAR. We hypothesized that statins may
ccelerate aneurysm sac regression after EVAR. The aim of
his study was to investigate the correlation between statin
se and aneurysm sac regression.
ETHODS
According to French legislation, no informed consent
as required from patients participating in this observa-
ional retrospective study.
Patient selection. Between January 2000 and August
009, 957 patients who underwent EVAR for AAAs at our
nstitution (Henri Mondor Hospital, Assistance Publique
ôpitaux de Paris, France) were registered prospectively in
computerized database. Because the type of stent graft has
een identified as a predictive factor of shrinkage,24 we only
ncluded patients treated with the Zenith device (Cook,
loomington, Ind). It was the most commonly used device
t our institution. Indications for EVAR were in agreement
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and Evaluation criteria.25,26We also treated EVAR patients
who refused open repair but whomet the anatomic require-
ments of the American consensus document, published in
1997.27
We excluded data of patients who did not meet the
criteria of treatment success proposed by the American
Vascular Surgery Society in 2002: absence of aneurysm-
related death, rupture or surgical conversion, stent graft
migration or failure, type I and III endoleaks, and type II
endoleaks responsible for aneurysmal growth.28 To limit
confounding factors, we excluded all patients presenting
any type of endoleak identified during follow-up. We also
excluded patients treated for thoracoabdominal aneurysm,
infectious, or inflammatory aneurysm, ruptured aneurysm,
isolated iliac aneurysm, or anastomotic pseudoaneurysm.
Data collection. As part of conventional care after
EVAR, patients automatically received a computer-gener-
ated notification of each appointment, including computed
tomography (CT) scan prescription with the date of the
examination. Follow-up information, including clinical
screening, duplex scan, and CT angiography, performed at
1, 6, 12, 18, and 24 months, and yearly thereafter, were
prospectively collected in a specific database (Logit, Fon-
tenay sous Bois, France).
End points. We compared the CT scan obtained be-
fore treatment and at the 24-month follow-up. We mea-
sured the maximal transverse aneurysm diameter, the max-
imal diameter of the common iliac arteries, the maximal
diameter of the infrarenal aorta (proximal neck diameter),
and the proximal neck length, which have been shown to
influence sac size regression in previous studies.23,29 The
end point was aneurysm sac regression, expressed as a
decrease of the preoperative largest diameter. We analyzed
two regression thresholds of 5 and 10 mm in maximal
aortic diameter. CT scans were reviewed by the vascular
surgeon in charge of the patient and by a vascular radiolo-
gist, who had to agree on the measurements before data
were entered in the database. Measurements were per-
formed on a Netvantage Windows Volume Show 3 plat-
form (Infragistics, Elstree, United Kingdom).
We studied the influence on sac regression of statin
therapy, of duration of statin therapy, and of anatomic
factors. If statins were introduced before surgery, the
choice of the drug was respected and was not modified
during the study.
We considered as statin users only the patients taking
statins every day during the study period, starting the day of
surgery or before. Changes in the dose or molecule (type of
statin) were exclusion criteria. An exclusion criterion for the
no statin-user patients was statin therapy before the proce-
dure and/or previous statin taking.
Statistical analysis. Statistical analysis was done with
Stata 10 software (StataCorp, College Station, Tex). Quan-
titative data are presented as means  standard deviations
and qualitative data as percentages. Quantitative variables
were compared using the Student t-test. Qualitative vari-
ables were compared using 2 or Fischer exact test when n s5 (level of significance P  .05). A multivariate analysis
y logistic regression included factors assessed in the uni-
ariate analysis with P  .1. Demographic and anatomic
actors that have been associated with sac size modifications
n the literature were forced into logistic regression to not
eglect confounding factors.
ESULTS
Demographics. Among the 957 patients who under-
ent EVAR, 665 were treated with a Zenith endograft.
fter exclusion of complex aneurysms (thoracoabdominal
neurysms, pararenal aneurysms), ruptured aneurysms,
onversion, and inflammatory or infectious aneurysms,
97 consecutive patients were suitable for the study. To
imit confounding factors, we excluded endoleaks (29.9%)
ecause they influence sac behavior. Among the 417 re-
aining patients, 163 died during the study period, and 88
ere lost to follow-up (Fig). Finally, 166 patients were
uitable for analysis. The control group comprised 46 pa-
ients who never had statin therapy pre-EVAR andwere not
iven statin therapy postoperatively. The statin group com-
rised 120 patients. In 52 patients, statin therapy has been
reviously introduced before the procedure, and 68 started
herapy the day before the intervention.
Introduction of long-term preoperative statin therapy
as not controlled in this study, but an anesthesiologist
ontrolled the relevance of statin therapy in each patient at
east 1 month before surgery. Maximum duration of pre-
perative therapy was 20 years (average duration of treat-
ent, 7 years). All cases of statin introduction before
957 EVAR
 665 Cook
597 AAA
(Zenith endograft)
TAA
Juxtarenal
Infectious
Inflammatory
Ruptured
aneurysms
346 patients
Death = 163
Lost follow up = 88
166 patients
(clinical success criteria)
Endoleaks = 180
No statin
n = 46
Statins
n = 120
Pre op
n = 52
Per op
n = 68
ig. Flow chart shows patient selection. AAA, Abdominal aortic
neurysm; EVAR, endovascular aneurysm repair; TAA, thoraco-
bdominal aneurysm.urgery were in accordance with French Health Products
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Volume 55, Number 6 Raux et al 1589Safety Agency requirements. Statin distribution is detailed
in Table I.
The minimum follow-up in all patients was 2 years, and
no deaths occurred in either group during this interval.
Both groups were similar, with no significant difference in
clinical variables (Table II), in preoperative largest aneu-
rysm diameter, maximal common iliac diameters, maximal
proximal neck diameter, and in proximal neck length (Ta-
ble III). As well, in the statin group, patients taking statins
before the procedure and patients starting to take statins
perioperatively were strictly comparable regarding demo-
graphics and anatomic variables: age (P  .31), sex (P 
.99), diabetes (P  .92), smoking (P  .78), aneurysm
diameter (P  .85), length and diameter of the proximal
neck (P  .54 and P  .26), and common iliac diameter
(P .64). No reinterventions, endograft complications, or
aortic-related events were observed.
Influence of statin therapy and anatomic factors.
The decrease in rate in maximal aortic diameter was 25% in
the statin group and 14% in the control group (P .0001).
In the statin group, treatment duration had no effect on
aortic diameter: the decrease in maximal aortic diameter
was similar in patients who received statins preoperatively
to those who started taking statins in the perioperative
course (27% vs 24%; P  .2). A long-term use (7 years)
did not affect the aneurysm reduction compared with pa-
tients who took statins for7 years (25% vs 27%; P .59).
Primary study end point was AAA sac shrinkage, de-
fined as a decrease of aneurysm maximal diameter from the
pre-EVAR CT scan to the post-EVAR CT scan scheduled
at the 24-month follow-up. We used a threshold of 5 and
10 mm. We performed univariate analysis of the influence
of each factor on AAA shrinkage at 24 months. Statin use
(odds ratio [OR], 7.93; 95% confidence interval [CI],
3.22-15.52) and maximal preoperative aneurysm diameter
(OR, 1.06; 95% CI, 1.01-1.12; P  .038) were predictive
factors of 5-mm shrinkage, and 10-mm decrease factors
Table I. Statin distribution
Statins No. (%)
Fluvastatin
80 mg 4 (3.3)
Simvastatin
20 mg 19 (15.9)
40 mg 3 (2.5)
Atorvastatin
10 mg 15 (12.5)
20 mg 12 (10)
40 mg 10 (8.3)
80 mg 1 (0.8)
Rosuvastatin
5 mg 18 (15)
10 mg 12 (10)
Pravastatin
10 mg 3 (2.5)
20 mg 17 (14.2)
40 mg 6 (5)were also statin therapy (OR, 3.75; 95%CI, 1.83-7.67) and ehe maximal preoperative aortic diameter (OR, 1.05; 95%
I, 1.01-1.1; P  .02).
As anatomic factors such as common iliac artery diam-
ter, maximal aneurysm diameter, neck diameter, and
ength had an influence on sac behavior in subsequent
tudies, they were forced into the multivariate analysis. The
ogistic regression model was adjusted for sex, age, diabe-
es, and smoking, which confirmed the influence of statin
herapy on aneurysm sac regression (Table IV).
ISCUSSION
This study demonstrates that statin therapy in patients
ho met the criteria of clinical success after EVAR with a
enith device was associated with an increase in sac shrink-
ge at 24months. Aneurysm diameter is a major criterion of
fficacy during the follow-up of EVAR.30 Its changes can
lter the follow-up sequences and have implication on the
urgical outcomes.
The variety of effects explain why statins are currently
ne of the most studied and prescribed drugs.18 Statin
herapy in patients with aortic diseases is known to improve
utcomes after EVAR or open repair.13,18 Many studies
howed controversial results of statin effects on AAA expan-
ion rate.15-18,31 Previous trials analyzed shrinkage factors
f the aneurysm sac after EVAR.23,29,32 In a recent large
tudy, Schanzer et al29 identified independent predictive
actors of AAA sac enlargement such as endoleak, age 80
ears, aortic neck diameter 28 mm, aortic neck angle
60°, and iliac artery diameter20 mm. However, to our
nowledge, our study is the first that has explored the
nfluence of statin therapy on sac regression.
The principal limitations of this study are the lack of
andomization and that patients who did not take statins
ere those who were treated in an earlier period in the
tudy. However, the correlation between statin use and sac
egression was strong, which we believe provides convinc-
ng clues on the efficacy of the drug. To limit the influence
f confounding factors, patients included in the series were
trictly selected with many exclusion criteria. First, we
ocused on patients who underwent EVAR with the Zenith
evice, because previous studies have shown that sac behav-
or after EVAR was device-specific24,33 and also because
his is the most commonly used device in our institution.
urthermore, we chose the Zenith graft because there was
o major change in its structure (stent composition, main
ody cover) over time, which could have interfered with sac
ehavior. The study of only one graft reduced the studied
opulation but was deemed mandatory to avoid bias. In-
tructions for use about aortic neck anatomy (60° angu-
ation) were respected.
Patients who did not meet criteria of treatment success
ere excluded. We excluded all types of endoleaks, which
re known to be a predictive factor of sac enlargement,32
neurysm-related death, rupture, device migration or fail-
re, and surgical conversion. Excluding all these events
educed the number of patients available for the study but
imited the effect of confounding factors so that the sole
ffect of statin therapy could be assessed. This reason
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study of Schanzer et al,29 who underlined the influence of
anatomic factors and the respect of companies’ instructions
for use.
We did not use volumetric assessment. Although seem-
ingly reliable, this method is difficult to apply routinely due
to time constraints.34 We then relied on diameter measure-
ments because they are reproducible for changes 5
Table II. Main clinical data in non-statin-group and statin
Variablea Total (n  166)
Age, years 71.5  0.7
Male 160 (96.4)
Obesity 45 (27.2)
COPD 26 (15.7)
Symptomatic carotid lesionsb 9 (5.42)
End-stage renal failure 5 (3)
Coronaropathy 35 (21.1)
Dyslipidemia 61 (36.7)
Hypertensionc 93 (56)
Active smoker 28 (16.9)
Diabetes mellitus 21 (12.6)
ASA classification
1 1 (2.2)
2 71 (43)
3 87 (52.7)
4 2 (1.2)
ASA, American Society of Anesthesiologists; COPD, chronic obstructive pu
aContinuous data are expressed as mean  standard deviation; categoric da
bOnset of any cerebrovascular disease, including transient ischemic attack o
cBlood pressure 140/90 mm Hg or taking one or more antihypertensive
Table III. Preoperative aneurysm anatomical criteria
Variables
Total, mm
Mean  SD mm
Max transverse diameter 53.15  8.6
Proximal neck
Max diameter 23.5  4.3
Length 26.2  12.9
Max common iliac artery diameter 18.2  9.1
SD, Standard deviation.
Table IV. Multivariate analysis of statin use and
anatomic factors on sac regressiona
Variable
5-mm regression 10-mm regression
OR (95% CI) OR (95% CI)
Statin use 9.39 (3.45-25.56) 4.35 (1.99-9.5)
Max external diameter 1.08 (1.1-1.15) 1.07 (1.02-1.12)
Proximal neck
Max diameter 0.97 (0.85-1.11) 0.94 (0.87-1.02)
Length 0.99 (0.95-1.02) 1.03 (1-1.06)
Max common iliac
artery diameter 1.03 (0.96-1.11) 0.99 (0.95-1.03)
CI, Confidence interval; OR, odds ratio.
aData adjusted for age, sex, diabetes, and smoking.mm.32,35,36 cWe did not evaluate the role of thrombus or plaque
ithin the proximal neck. Previous studies have shown
heir potential influence on sac shrinkage, as circumferen-
ial thrombus in the neck may inhibit shrinkage by pressure
ransmission through thrombus into the sac.32
Despite the absence of clear relation between total
holesterol and AAA, several studies and meta-analyses
ave highlighted an influence of statin therapy on aneurysm
rowth.15-17,31 However, these results are disputed by a
ecent meta-analysis.18 Depletion of smooth muscle cells,
egradation of aortic wall proteins, and inflammation are
he principal causes of aneurysm formation, mediated by
he proinflammatory matrix metalloproteases (MMPs), es-
ecially MMP-2 and MMP-9.37,38 MMP-9, also called
elatinase B, which cleaves elastin, collagen, and fibrino-
en, appears to have a fundamental role in aneurysm for-
ation.38 MMP-9 levels decrease after open or endovascu-
ar treatment. Patients with persistent elevated MMP-9
evels after EVAR may be at higher risk of endoleaks.39
MP-2, like MMP-9, cleaves type IV collagen and elastin,
wo proteases that appear to work synergistically on aneu-
ysm formation.40 Statin therapy reduces their concentra-
ion in the aortic wall,7,8,11,12 which constitutes the prin-
up patients
onstatin (n  46) Statin (n  120) P
72.9  1.3 70.9  0.8 .18
44 (95.6) 116 (96.7) .75
9 (19.6) 36 (30.2) .16
7 (15.22) 19 (15.83) .92
2 (4.35) 7 (5.83) .52
1 (2.17) 4 (3.33) .57
10 (21.7) 35 (20.8) .9
13 (28.3) 48 (40) .16
22 (47.8) 71 (59.2) .19
6 (13) 22 (18.3) .41
4 (8.7) 17 (14.2) .25
4 (3.4) 5 (3.0)
22 (47.8) 49 (41.2)
22 (47.8) 65 (54.6) .665
1 (2.2) 1 (0.8)
ary disease.
umber (%).
e due to a carotid stenosis.
Nonstatin Statin
Mean  SD mm Mean  SD mm P
53.8  10.6 52.9  7.8 .54
22.74  4.9 23.8  4.1 .24
27.4  17.9 25.76  10.4 .46
18  8.1 18.25  9.5 .86-gro
N
lmon
ta as nipal hypothesis of statin efficacy. In the light of our results,
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length has no effect on sac evolution.
The wide variety of statins used by patients does not
allow us to reach conclusions about the effect of one drug
or on one efficient dose. But differences of treatment in the
statin group allow us to suppose that there is a positive
effect of this therapeutic class, more than a given molecule.
No complications of statin use (rhabdomyolysis, hepa-
titis, or acute liver failure) were documented during follow-
up. Liver enzyme measurements were obtained for each
patient before statins were introduced, and a new measure
was performed at 3 months to ensure the absence of com-
plications.
CONCLUSIONS
This study shows a beneficial effect of statins on sac
regression, which to our knowledge has not been explored
before. We strongly believe that currently, statin therapy
should be prescribed after EVAR not only for its role in the
prevention of cardiovascular events but also as a way of
improving EVAR efficacy.
Statin therapy, even begun the day of EVAR, appears to
be strongly associated with aneurysm sac regression.
Whereas a randomized study seems difficult to undertake,
this new pleiotropic effect should be further investigated. If
this effect is confirmed, it reinforces the necessity of statin
therapy for patients scheduled for EVAR, in addition to
benefits on morbidity and mortality. It may improve out-
comes and allows lightening of the follow-up.
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